Control of a Candida glabrata prosthetic endovascular infection with posaconazole

References

• LaBerge JM, Ring EJ, Gordon RL, et al. Creation of transjugular intrahepatic portosystemic shunts with the wallstent endoprosthesis: results in 100 patients. Radiology 1993; 187: 413–420
   PubMed Web of Science ®Google Scholar
• Armstrong PK, MacLeod C. Infection of transjugular intrahepatic portosystemic shunt devices: three cases and a review of the literature. Clin Infect Dis 2003; 36: 407–412
   Google Scholar
• Deibert P, Schwarz S, Olschewski M, et al. Risk factors and prevention of early infection after implantation or revision of transjugular intrahepatic portosystemic shunts: results of a randomized study. Dig Dis Sci 1998; 43: 1708–1713
   Google Scholar
• DeSimone JA, Beavis KG, Eschelman DJ, Henning KJ. Sustained bacteremia associated with transjugular intrahepatic portosystemic shunt (TIPS). Clin Infect Dis 2000; 30: 384–386
   Google Scholar
• Sanyal AJ, Reddy KR. Vegetative infection of transjugular intrahepatic portosystemic shunts. Gastroenterology 1998; 115: 110–115
   PubMed Web of Science ®Google Scholar
• Schiano TD, Atillasoy E, Fiel MI, et al. Fatal fungemia resulting from an infected transjugular intrahepatic portosystemic shunt stent. Am J Gastroenterol 1997; 92: 709–710
   Google Scholar
• Zaman MM, Recco R, Tejwani U, et al. Case of vancomycin-resistant Enterococcus faecium infection associated with a transjugular intrahepatic portosystemic shunt that was treated with quinupristin/dalfopristin after bacteremia persisted with alatrofloxacin therapy. Clin Infect Dis 1999; 29: 954–955
   Google Scholar
• Brown RS, Jr, Brumage L, Yee HF, Jr, et al. Enterococcal bacteremia after transjugular intrahepatic portosystemic shunts (TIPS). Am J Gastroenterol 1998; 93: 636–639
   Google Scholar
• Eversman D, Chalasani N. A case of infective endotipsitis. Gastroenterology 1999; 117: 514
   Google Scholar
• Darwin P, Mergner W, Thuluvath P. Torulopsis glabrata fungemia as a complication of a clotted transjugular intrahepatic portosystemic shunt. Liver Transpl Surg 1998; 4: 89–90
   Google Scholar
• National Committee for Clinical Laboratory Standards (NCCLS). Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi: proposed standard M38P. Wayne, PA: NCCLS, 1998.
   Google Scholar
• Gulberg V, Deibert P, Ochs A, et al. Prevention of infectious complications after transjugular intrahepatic portosystemic shunt in cirrhotic patients with a single dose of ceftriaxone. Hepatogastroenterology 1999; 46: 1126–1130
   Google Scholar
• Gumbo T, Isada CM, Hall G, et al. Candida glabrata fungemia. Clinical features of 139 patients. Medicine (Baltimore) 1999; 78: 220–227
   Web of Science ®Google Scholar
• Garbino J, Kolarova L, Rohner P, et al. Secular trends of candidemia over 12 years in adult patients at a tertiary care hospital. Medicine (Baltimore) 2002; 81: 425–433
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 2004; 10(Suppl. 1)11–23
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Jones RN, Messer SA, et al. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE program. SCOPE participant group. Surveillance and control of pathogens of epidemiologic. Diagn Microbiol Infect Dis 1998; 30: 121–129
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Hollis RJ, Jones RN. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother 2001; 45: 2862–2864
   PubMed Web of Science ®Google Scholar
• Fidel PL, Jr, Vazquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev 1999; 12: 80–96
   PubMed Web of Science ®Google Scholar
• Komshian SV, Uwaydah AK, Sobel JD, Crane LR. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 1989; 11: 379–390
   PubMedGoogle Scholar
• Hitchcock CA, Pye GW, Troke PF, et al. Fluconazole resistance in Candida glabrata. Antimicrob Agents Chemother 1993; 37: 1962–1965
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Boyken L, et al. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systematically active antifungal agents: a global assessment from the ARTEMIS antifungal surveillance program conducted in 2001 and 2002. J Clin Microbiol 2004; 42: 3142–3146
   PubMed Web of Science ®Google Scholar
• Westphal JF, Brogard JM. Drug administration in chronic liver disease. Drug Safety 1997; 1: 47–73
   Google Scholar
• Cuenca-Estrella M, Diaz-Guerra TM, Mellado E, Rodriguez-Tudela JL. Flucytosine primary resistance in Candida species and Cryptococcus neoformans. Eur J Clin Microbiol Infect Dis 2001; 20: 276–279
   PubMed Web of Science ®Google Scholar
• Drago M, Scaltrito MM, Morace G, group GISIA-2. In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei. Eur J Clin Microbiol Infect Dis 2004; 23: 619–624
   PubMed Web of Science ®Google Scholar
• Law D, Moore CB, Denning DW. Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. Antimicrob Agents Chemother 1997; 41: 2310–2311
   PubMed Web of Science ®Google Scholar
• Munayyer HK, Mann PA, Chau AS, et al. Posaconazole is a potent inhibitor of sterol 14α-demethylation in yeasts and molds. Antimicrob Agents Chemother 2004; 48: 3690–3696
   PubMed Web of Science ®Google Scholar
• Polak, A. Multicenter study of standardization of sensitivity testing of fungi to 5-fluorocytosine and amphotericin B. Mykosen, 30: 306–308.
   Google Scholar
• Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003; 36: 1221–1228
   PubMed Web of Science ®Google Scholar
• Perea S, Gonzalez G, Fothergill AW, et al. In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles. J Clin Microbiol 2002; 40: 1831–1833
   PubMed Web of Science ®Google Scholar
• Barchiesi F, Spreghini E, Maracci M, et al. In vitro activities of voriconazole in combination with three antifungal agents against Candida glabrata. Antimicrob Agents Chemother 2004; 48: 3317–3322
   PubMed Web of Science ®Google Scholar